Page 296 of 857: studies 2,951 to 2,960 of 8,563, newest first. Back to the addiction overview
Synfacts April 22, 2025 Dirk Trauner, Daniel W. Zuschlag
Keywords ibogaine - anti-addictive - modular synthesis Publication History Article published online: 22 April 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Psychoactives April 22, 2025 Kerem Kemal Soylemez, Emma Marie de Boo, Joanne Lusher 7 citations
Psychedelic substances have recently emerged as a promising method for treating mental health conditions, despite a history of stigmatization and restriction in use. The present review synthesizes existing literature on the therapeutic potential of psychedelics such as LSD, psilocybin, and MDMA in addressing specific mental health conditions like depression, anxiety, and addiction. On reviewing...
Behavioral and Brain Sciences April 21, 2025 Anil K. Seth 1 citation
As artificial intelligence (AI) continues to advance, it is natural to ask whether AI systems can be not only intelligent, but also conscious. I consider why people might think AI could develop consciousness, identifying some biases that lead us astray. I ask what it would take for conscious AI to be a realistic prospect, challenging the assumption that computation provides a sufficient basis...
Scientific Reports April 21, 2025 Nilubon Thaoboonruang, Ornrat Lohitnavy, Kimheang Ya et al. 4 citations
Psilocybin is an active alkaloid found in magic mushrooms (Psilocybe cubensis). It is classified as a Class I Psychoactive Substance due to its psychoactive properties. Recent research has suggested that psilocybin holds potential for treating major depressive disorder. The objective of this study was to develop a physiologically based pharmacokinetic (PBPK) model for psilocybin and its active...
Archives of Toxicology April 19, 2025 António B Pimpão, Luísa Teixeira-Santos, Nuno R Coelho et al.
We were pioneers in describing aryl hydrocarbon receptor (AhR) activation by chronic intermittent hypoxia (CIH) in a rat pre-clinical model. This model mimics hypertension (HTN) secondary to obstructive sleep apnea, enabling longitudinal investigation of hypertension development. Concerns about the influence of barbiturates on AhR-regulated enzymes led us to opt for ketamine/medetomidine...
Neuropsychopharmacology April 19, 2025 Valeria Grasso, Joseph Tennyson, Raag D. Airan et al. 5 citations
Subanesthetic ketamine is currently used as a rapid-acting treatment for varied neuropsychiatric disorders. However, the mechanistic underpinnings of its therapeutic action remain unclear, and emerging clinical and preclinical evidence highlights a potential involvement of the opioid system. We used pharmacological functional ultrasound imaging data acquired during and after ketamine...
Journal of Psychoactive Drugs April 18, 2025 Damian Swieczkowski, Aleksander Kwaśny, Krzysztof Sadko et al. 1 citation
Ibogaine, a non-classical psychedelic, has gained increasing attention as a potential treatment for substance use disorders (SUD); however, a lack of commercial interest and safety-related concerns limit its clinical development. This cross-sectional study investigates the current landscape of clinical trials involving ibogaine, a non-classical psychedelic, focusing on its safety and efficacy....
International Journal of Arts, Humanities & Social Science April 17, 2025 Jada Zehner, Kelly Arney
Anxiety is a widespread mental health concern that significantly impacts daily functioning and overall well-being for a portion of the overall population. Mindfulness-Based Stress Reduction (MBSR) has sparked interest as a therapeutic approach integrating mindfulness meditation and yoga to promote self-awareness, emotional regulation, and stress resilience. This literature review examines the...
Pharmacopsychiatry April 17, 2025 Aleksander Kwaśny, Zuzanna Gaca, Damian Swieczkowski et al. 2 citations
Abstract Regulatory compliance is crucial in the clinical development of psychedelic substances, including psilocybin. This study aimed to examine the alignment of clinical trial protocols for psilocybin in the treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD) with established regulatory requirements. A cross-sectional investigation was conducted on...
Proceedings of the National Academy of Sciences April 14, 2025 Jeremy R Tuck, Lee E. Dunlap, Yara A Khatib et al. 32 citations
Decreased dendritic spine density in the cortex is a key pathological feature of neuropsychiatric diseases including depression, addiction, and schizophrenia (SCZ). Psychedelics possess a remarkable ability to promote cortical neuron growth and increase spine density; however, these compounds are contraindicated for patients with SCZ or a family history of psychosis. Here, we report the...